JBC Anatrace, Inc.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M503065200 on October 21, 2005

J. Biol. Chem., Vol. 280, Issue 51, 42016-42025, December 23, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/51/42016    most recent
M503065200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kushiyama, A.
Right arrow Articles by Asano, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kushiyama, A.
Right arrow Articles by Asano, T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Resistin-like Molecule {beta} Activates MAPKs, Suppresses Insulin Signaling in Hepatocytes, and Induces Diabetes, Hyperlipidemia, and Fatty Liver in Transgenic Mice on a High Fat Diet*

Akifumi Kushiyama{ddagger}, Nobuhiro Shojima{ddagger}, Takehide Ogihara§, Kouichi Inukai¶, Hideyuki Sakoda{ddagger}, Midori Fujishiro{ddagger}, Yasushi Fukushima{ddagger}, Motonobu Anai||, Hiraku Ono||, Nanao Horike**, Amelia Y. I. Viana**, Yasunobu Uchijima**, Koichi Nishiyama**, Tatsuo Shimosawa{ddagger}, Toshiro Fujita{ddagger}, Hideki Katagiri§, Yoshitomo Oka§, Hiroki Kurihara**, and Tomoichiro Asano**1

From the {ddagger}Department of Internal Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, the §Division of Advanced Therapeutics for Metabolic Diseases, Center for Translational and Advanced Animal Research on Human Diseases, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Sendai, Miyagi 980-8574, the Division of Endocrinology and Diabetes, Department of Medicine, Saitama Medical School, Morohongo 38, Moroyama, Iruma-gun, Saitama 350-0495, the ||Department of Internal Medicine, Institute for Adult Diseases, Asahi Life Foundation, 1-6-1, Marunouchi, Chiyodaku, Tokyo 100-0005, and the **Department of Physiological Chemistry and Metabolism, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan

Resistin and resistin-like molecules (RELMs) are a family of proteins reportedly related to insulin resistance and inflammation. Because the serum concentration and intestinal expression level of RELM{beta} were elevated in insulin-resistant rodent models, in this study we investigated the effect of RELM{beta} on insulin signaling and metabolism using transgenic mice and primary cultured hepatocytes. First, transgenic mice with hepatic RELM{beta} overexpression were shown to exhibit significant hyperglycemia, hyperlipidemia, fatty liver, and pancreatic islet enlargement when fed a high fat diet. Hyperinsulinemic glucose clamp showed a decreased glucose infusion rate due to increased hepatic glucose production. In addition, the expression levels of IRS-1 and IRS-2 proteins as well as the degrees of insulin-induced phosphatidylinositol 3-kinase and Akt activations were attenuated in RELM{beta} transgenic mice. Similar down-regulations of IRS-1 and IRS-2 proteins were observed in primary cultured hepatocytes chronically treated (for 24 h) with RELM{beta}, suggesting the insulin resistance-inducing effect of RELM{beta} to be direct. Furthermore, it was shown that RELM{beta} acutely and markedly activates ERK and p38, while weakly activating JNK, in primary cultured hepatocytes. This increased basal p38 phosphorylation level was also observed in the livers of RELM{beta} transgenic mice. In conclusion, RELM{beta}, a gut-derived hormone, impairs insulin signaling probably via the activations of classic MAPKs, and increased expression of RELM{beta} may be involved in the pathogenesis of glucose intolerance and hyperlipidemia in some insulin-resistant models. Thus, RELM{beta} is a potentially useful marker for assessing insulin resistance and may also be a target for future novel anti-diabetic agents.


Received for publication, March 21, 2005 , and in revised form, October 18, 2005.

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed. Tel.: 81-3-5841-3603; Fax: 81-3-5803-1874; E-mail: asano-tky{at}umin.ac.jp.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
Y. Koketsu, H. Sakoda, M. Fujishiro, A. Kushiyama, Y. Fukushima, H. Ono, M. Anai, T. Kikuchi, T. Fukuda, H. Kamata, et al.
Hepatic overexpression of a dominant negative form of raptor enhances Akt phosphorylation and restores insulin sensitivity in K/KAy mice
Am J Physiol Endocrinol Metab, April 1, 2008; 294(4): E719 - E725.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.